WHO member states must develop, adopt treaty to combat substandard, fake medicines

Published on November 22, 2012 at 4:56 AM · No Comments

"This week delegates from about 100 member countries of the World Health Organization are meeting in Buenos Aires with the aim of strengthening defenses against substandard and fraudulent medicines," Amir Attaran of the University of Ottawa and Roger Bate, a resident scholar at the American Enterprise Institute, write in a New York Times opinion piece. "The meeting is extremely important, but to make progress a number of hurdles will have to be overcome," they say, noting a paper recently published in the BMJ outlines such challenges. "In Buenos Aires, the delegates first need to agree which medicines are good and which are bad," the authors say, adding, "[C]ountries need to agree that protecting intellectual property and public health are two different things." Unless countries define the "difference between honest drug companies that sell accidentally substandard medicines, and organized criminals who sell a deliberately falsified ... drug," then "criminals will continue to slip through loopholes and honest companies, pharmacists and doctors will find themselves prosecuted unjustly," they write.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post